31 May 2024

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Posting of Annual Report and Notice of AGM

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December 2023 and the Notice of the 2024 Annual General Meeting ("AGM") are now available on the Company's website at www.avacta.com/investors/documents.  

Copies of the Annual Report and Accounts and the Notice of the AGM have been posted to registered shareholders who have elected to receive them in paper form.

The Annual General Meeting will be held on Wednesday, 26 June 2024 at 10:30 AM BST at Glaziers Hall, 9 Montague Close, London Bridge, London, SE1 9DD (the "Venue").

The Venue has a capacity of approximately 200 people. Registered shareholders have a right to attend the AGM.  In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing ICR Consilium at avacta@consilium-comms.com by Friday, 21 June 2024. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).

Only registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.

The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website later that day for shareholders who are not able to attend in person.

Early pre-registration to attend the AGM in person is recommended as the Venue's capacity is limited (as referred to above) and, for non-registered shareholders, registrations will be dealt with on a first come, first served basis. All presentation materials will be made available on the website at the end of the day and no new material information will be provided.

-Ends-

For further information from Avacta Group plc, please contact:

About Avacta Group plc - www.avacta.com

Avacta is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta Therapeutics is a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer^®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumor compared with healthy tissues. The pre|CISION™ platform harnesses this tumor specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumor microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to www.avacta.com/Investors/Investor-news-email-alerts/